Okada S
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
Semin Liver Dis. 1999;19(3):323-8. doi: 10.1055/s-2007-1007121.
Several local ablation methods, most of which can be performed percutaneously under imaging guidance, have recently been developed as minimally invasive therapy for hepatocellular carcinoma (HCC). Among these, percutaneous ethanol injection has been the most widely performed and is now accepted as an attractive alternative to surgery in patients with small HCC. Other local ablation therapeutic options to achieve more effective tumor necrosis with less invasiveness have also been developed. Some of these techniques, such as microwave coagulation therapy and radiofrequency ablation, have already been introduced clinically. However, the real role of these new ablation methods in the treatment of HCC remains to be determined because of the lack of randomization and the small number of patients in the published series. Therefore, further trials, possibly randomized trials to compare the results of different options, are mandatory. Moreover, the prevention of recurrence after local ablation therapy for HCC has become an urgent problem to be resolved.
最近,已开发出几种局部消融方法,其中大多数可以在成像引导下经皮进行,作为肝细胞癌(HCC)的微创治疗方法。其中,经皮乙醇注射是应用最广泛的,目前已被认为是小肝癌患者手术的一种有吸引力的替代方法。还开发了其他局部消融治疗方案,以在侵入性较小的情况下实现更有效的肿瘤坏死。其中一些技术,如微波凝固治疗和射频消融,已经应用于临床。然而,由于已发表系列研究缺乏随机分组且患者数量较少,这些新的消融方法在肝癌治疗中的实际作用仍有待确定。因此,必须进行进一步的试验,可能是随机试验,以比较不同方案的结果。此外,肝癌局部消融治疗后预防复发已成为亟待解决的问题。